1. Home
  2. NBTX vs JYNT Comparison

NBTX vs JYNT Comparison

Compare NBTX & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NBTX
  • JYNT
  • Stock Information
  • Founded
  • NBTX 2003
  • JYNT 2010
  • Country
  • NBTX France
  • JYNT United States
  • Employees
  • NBTX N/A
  • JYNT N/A
  • Industry
  • NBTX Biotechnology: Pharmaceutical Preparations
  • JYNT Multi-Sector Companies
  • Sector
  • NBTX Health Care
  • JYNT Miscellaneous
  • Exchange
  • NBTX Nasdaq
  • JYNT Nasdaq
  • Market Cap
  • NBTX 211.9M
  • JYNT 170.3M
  • IPO Year
  • NBTX 2020
  • JYNT 2014
  • Fundamental
  • Price
  • NBTX $9.85
  • JYNT $10.87
  • Analyst Decision
  • NBTX Strong Buy
  • JYNT Strong Buy
  • Analyst Count
  • NBTX 1
  • JYNT 3
  • Target Price
  • NBTX $8.00
  • JYNT $16.33
  • AVG Volume (30 Days)
  • NBTX 15.0K
  • JYNT 69.8K
  • Earning Date
  • NBTX 09-17-2025
  • JYNT 08-07-2025
  • Dividend Yield
  • NBTX N/A
  • JYNT N/A
  • EPS Growth
  • NBTX N/A
  • JYNT N/A
  • EPS
  • NBTX N/A
  • JYNT N/A
  • Revenue
  • NBTX N/A
  • JYNT $53,449,713.00
  • Revenue This Year
  • NBTX N/A
  • JYNT $8.06
  • Revenue Next Year
  • NBTX $74.67
  • JYNT $11.18
  • P/E Ratio
  • NBTX N/A
  • JYNT N/A
  • Revenue Growth
  • NBTX N/A
  • JYNT 277.36
  • 52 Week Low
  • NBTX $2.76
  • JYNT $9.58
  • 52 Week High
  • NBTX $10.59
  • JYNT $13.47
  • Technical
  • Relative Strength Index (RSI)
  • NBTX 75.73
  • JYNT 48.99
  • Support Level
  • NBTX $8.20
  • JYNT $10.18
  • Resistance Level
  • NBTX $10.59
  • JYNT $11.00
  • Average True Range (ATR)
  • NBTX 0.51
  • JYNT 0.44
  • MACD
  • NBTX 0.18
  • JYNT -0.01
  • Stochastic Oscillator
  • NBTX 79.95
  • JYNT 65.47

About NBTX Nanobiotix S.A.

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

Share on Social Networks: